Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy

Cancer Communications

Table 4 Changes in LMR and benefits of chemotherapy

Pre- and post-chemotherapy LMR	No. of patients	Progression-free survival (months)			Overall survival (months)
Pre- and post-chemotherapy LMR	No. of patients	Median (95% CI)	HR (95% CI)	P value	Median (95% CI)	HR (95% CI)	P value*
Low–low	87	5.8 (5.1–6.5)	1		13.0 (10.3–15.7)	1
Low–high	129	8.4 (7.7–9.1)	0.524 (0.391–0.702)	<0.001	17.8 (16.9–18.7)	0.522 (0.371–0.771)	<0.001
High–low	151	8.2 (7.8–8.6)	0.733 (0.636–0.846)	<0.001	17.0 (15.6–18.4)	0.837 (0.699–1.003)	0.053
High–high	121	10.6 (9.8–11.4)	0.631 (0.566–0.702)	<0.001	22.2 (21.0–23.4)	0.636 (0.562–0.719)	<0.001

Abbreviations as in Tables 1 and 2
*Tested by COX proportional hazards model in which the reference is the low–low group, and adjusted with the ECOG performance status, number of metastatic sites, and differentiation